bupropion has been researched along with Lassitude in 21 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to systematically assess the evidence on the efficacy and safety of bupropion in the treatment of fatigue in people with cancer and non-cancer conditions." | 9.41 | Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review. ( Correa-Morales, JE; Cuellar-Valencia, L; Giraldo-Moreno, S; Iriarte-Aristizábal, MF; Mantilla-Manosalva, N; Quintero-Muñoz, E; Rodríguez-Campos, LF, 2023) |
| "A randomized, double-blind, placebo-controlled trial will examine the effects of bupropion on cancer-related fatigue." | 9.34 | A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures. ( Babilonia, MB; Bower, J; Cole, S; Culakova, E; Desta, Z; Han, HS; Heckler, C; Hoogland, AI; Janelsins, M; Jim, HSL; Morrow, G; Peppone, L; Williams, GC, 2020) |
| "Unlike selective serotonin reuptake inhibitors (SSRIs), bupropion may be classified as a dual noradrenaline and dopamine reuptake inhibitor, a difference with potential implications for the treatment of residual sleepiness and fatigue in major depressive disorder (MDD)." | 9.19 | Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. ( Cooper, JA; Papakostas, GI; Tucker, VL, 2014) |
| "This preliminary study investigated whether bupropion sustained release (SR) improved symptomatic fatigue, depression and quality of life in cancer patients and caregiver quality of life." | 9.12 | An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. ( Forsyth, P; Moss, EL; Pelletier, G; Simpson, JS, 2006) |
| "Improvement of fatigue in patients with multiple sclerosis (MS) who were given bupropion has been previously reported, but scales for lethargy and depression were not used." | 7.76 | Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis. ( De Sarro, G; Gallelli, L; Loiacono, D; Siniscalchi, A; Tolotta, GA, 2010) |
| "To demonstrate that bupropion sustained release (SR) can reduce the symptoms of fatigue experienced by cancer patients." | 7.72 | Bupropion sustained release treatment reduces fatigue in cancer patients. ( Cullum, JL; Pelletier, G; Simpson, JS; Wojciechowski, AE, 2004) |
| "Bupropion was administered 75 mg twice daily for twelve weeks." | 7.30 | The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial. ( Azizi, H; Baghbanian, SM; Bakhshi, A; Ghazaeian, M; Khalili, B, 2023) |
| "Bupropion was administered 75 mg/day for the first three days and 150 mg/day (divided in two doses) till the end of the study at week 6." | 6.94 | Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial. ( Azimi, S; Borhani, S; Hendouei, N; Janbabai, G; Saghafi, F; Salehifar, E; Zaboli, E, 2020) |
| "Bupropion is an atypical antidepressant, chemically unrelated to classical agents such as tricyclic antidepressants, selective serotonin reuptake inhibitors and other contemporary antidepressants." | 6.44 | Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. ( Han, C; Lee, C; Lim, HK; Masand, PS; Pae, CU; Patkar, AA; Steffens, DC, 2007) |
| "This study aimed to systematically assess the evidence on the efficacy and safety of bupropion in the treatment of fatigue in people with cancer and non-cancer conditions." | 5.41 | Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review. ( Correa-Morales, JE; Cuellar-Valencia, L; Giraldo-Moreno, S; Iriarte-Aristizábal, MF; Mantilla-Manosalva, N; Quintero-Muñoz, E; Rodríguez-Campos, LF, 2023) |
| "A randomized, double-blind, placebo-controlled trial will examine the effects of bupropion on cancer-related fatigue." | 5.34 | A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures. ( Babilonia, MB; Bower, J; Cole, S; Culakova, E; Desta, Z; Han, HS; Heckler, C; Hoogland, AI; Janelsins, M; Jim, HSL; Morrow, G; Peppone, L; Williams, GC, 2020) |
| "Unlike selective serotonin reuptake inhibitors (SSRIs), bupropion may be classified as a dual noradrenaline and dopamine reuptake inhibitor, a difference with potential implications for the treatment of residual sleepiness and fatigue in major depressive disorder (MDD)." | 5.19 | Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. ( Cooper, JA; Papakostas, GI; Tucker, VL, 2014) |
| "This preliminary study investigated whether bupropion sustained release (SR) improved symptomatic fatigue, depression and quality of life in cancer patients and caregiver quality of life." | 5.12 | An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. ( Forsyth, P; Moss, EL; Pelletier, G; Simpson, JS, 2006) |
| "Intensive longitudinal data from a randomized placebo-controlled smoking cessation trial (N=1504) are used to estimate a dynamical model of withdrawal-related processes including momentary craving, negative affect, quitting self-efficacy, and cessation fatigue for each of six treatment conditions (nicotine patch, nicotine lozenge, bupropion, patch + lozenge, bupropion + lozenge, and placebo)." | 3.85 | Evaluating the effect of smoking cessation treatment on a complex dynamical system. ( Bekiroglu, K; Lagoa, CM; Lanza, ST; Piper, ME; Russell, MA, 2017) |
| "Improvement of fatigue in patients with multiple sclerosis (MS) who were given bupropion has been previously reported, but scales for lethargy and depression were not used." | 3.76 | Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis. ( De Sarro, G; Gallelli, L; Loiacono, D; Siniscalchi, A; Tolotta, GA, 2010) |
| "To demonstrate that bupropion sustained release (SR) can reduce the symptoms of fatigue experienced by cancer patients." | 3.72 | Bupropion sustained release treatment reduces fatigue in cancer patients. ( Cullum, JL; Pelletier, G; Simpson, JS; Wojciechowski, AE, 2004) |
| "Bupropion was administered 75 mg twice daily for twelve weeks." | 3.30 | The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial. ( Azizi, H; Baghbanian, SM; Bakhshi, A; Ghazaeian, M; Khalili, B, 2023) |
| "Bupropion was administered 75 mg/day for the first three days and 150 mg/day (divided in two doses) till the end of the study at week 6." | 2.94 | Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial. ( Azimi, S; Borhani, S; Hendouei, N; Janbabai, G; Saghafi, F; Salehifar, E; Zaboli, E, 2020) |
| "Exercise fatigue was associated with an 8 ± 11% reduction in the peak velocity of prosaccades, and a 10 ± 11% decrement in antisaccade peak velocity." | 2.84 | Fatigue-related impairments in oculomotor control are prevented by norepinephrine-dopamine reuptake inhibition. ( Connell, CJ; Gant, N; Srzich, A; Thompson, B; Turuwhenua, J, 2017) |
| "Bupropion XL was superior to placebo at endpoint in reducing the IDS-IVR-30 total score (p = ." | 2.72 | Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. ( Hampton, KD; Jefferson, JW; Krishen, A; Modell, JG; Nelson, JC; Rush, AJ; VanMeter, SA; Wightman, DS, 2006) |
| "Bupropion is an atypical antidepressant, chemically unrelated to classical agents such as tricyclic antidepressants, selective serotonin reuptake inhibitors and other contemporary antidepressants." | 2.44 | Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. ( Han, C; Lee, C; Lim, HK; Masand, PS; Pae, CU; Patkar, AA; Steffens, DC, 2007) |
| "Fatigue and sleepiness (hypersomnia) are symptoms that are highly prevalent in patients with major depressive disorder (MDD)." | 2.43 | Symptoms of fatigue and sleepiness in major depressive disorder. ( Baldwin, DS; Papakostas, GI, 2006) |
| "Fatigue was assessed with the Modified Fatigue Impact Scale (MFIS)." | 1.39 | Reward responsiveness and fatigue in multiple sclerosis. ( Capello, E; Krueger, F; Mancardi, G; Pardini, M; Uccelli, A, 2013) |
| " No clinically significant bupropion-related changes in blood pressure, pulse rates, respiration rate, body temperature, or laboratory parameters were recorded; only 41 patients were discontinued due to intolerance to adverse experiences." | 1.27 | Private practice evaluation of the safety and efficacy of bupropion in depressed outpatients. ( Harto-Truax, N; Kirksey, DF, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 5 (23.81) | 2.80 |
| Authors | Studies |
|---|---|
| Correa-Morales, JE | 1 |
| Cuellar-Valencia, L | 1 |
| Mantilla-Manosalva, N | 1 |
| Quintero-Muñoz, E | 1 |
| Iriarte-Aristizábal, MF | 1 |
| Giraldo-Moreno, S | 1 |
| Rodríguez-Campos, LF | 1 |
| Baghbanian, SM | 3 |
| Khalili, B | 3 |
| Bakhshi, A | 3 |
| Azizi, H | 3 |
| Ghazaeian, M | 3 |
| Salehifar, E | 1 |
| Azimi, S | 1 |
| Janbabai, G | 1 |
| Zaboli, E | 1 |
| Hendouei, N | 1 |
| Saghafi, F | 1 |
| Borhani, S | 1 |
| Jim, HSL | 1 |
| Hoogland, AI | 1 |
| Han, HS | 1 |
| Culakova, E | 1 |
| Heckler, C | 1 |
| Janelsins, M | 1 |
| Williams, GC | 1 |
| Bower, J | 1 |
| Cole, S | 1 |
| Desta, Z | 1 |
| Babilonia, MB | 1 |
| Morrow, G | 1 |
| Peppone, L | 1 |
| Hashash, JG | 1 |
| Knisely, MR | 1 |
| Germain, A | 1 |
| McAuliff, K | 1 |
| Strassburger, M | 1 |
| Vachon, A | 1 |
| Binion, DG | 1 |
| Regueiro, M | 1 |
| Wallace, M | 1 |
| Szigethy, E | 1 |
| Bekiroglu, K | 1 |
| Russell, MA | 1 |
| Lagoa, CM | 1 |
| Lanza, ST | 1 |
| Piper, ME | 1 |
| Ashrafi, F | 1 |
| Mousavi, S | 1 |
| Karimi, M | 1 |
| Kojima, G | 1 |
| Tamai, A | 1 |
| Karino, S | 1 |
| Yuasa, M | 1 |
| Epure, J | 1 |
| Tsuzaki, B | 1 |
| Tanabe, M | 1 |
| Barsevick, AM | 1 |
| Irwin, MR | 1 |
| Hinds, P | 1 |
| Miller, A | 1 |
| Berger, A | 1 |
| Jacobsen, P | 1 |
| Ancoli-Israel, S | 1 |
| Reeve, BB | 1 |
| Mustian, K | 1 |
| O'Mara, A | 1 |
| Lai, JS | 1 |
| Fisch, M | 1 |
| Cella, D | 1 |
| Cooper, JA | 1 |
| Tucker, VL | 1 |
| Papakostas, GI | 2 |
| Connell, CJ | 1 |
| Thompson, B | 1 |
| Turuwhenua, J | 1 |
| Srzich, A | 1 |
| Gant, N | 1 |
| Siniscalchi, A | 1 |
| Gallelli, L | 1 |
| Tolotta, GA | 1 |
| Loiacono, D | 1 |
| De Sarro, G | 1 |
| Pardini, M | 1 |
| Capello, E | 1 |
| Krueger, F | 1 |
| Mancardi, G | 1 |
| Uccelli, A | 1 |
| Paul, MA | 1 |
| Gray, G | 1 |
| Kenny, G | 1 |
| Lange, M | 1 |
| Cullum, JL | 1 |
| Wojciechowski, AE | 1 |
| Pelletier, G | 2 |
| Simpson, JS | 2 |
| Moss, EL | 1 |
| Forsyth, P | 1 |
| Jefferson, JW | 1 |
| Rush, AJ | 1 |
| Nelson, JC | 1 |
| VanMeter, SA | 1 |
| Krishen, A | 1 |
| Hampton, KD | 1 |
| Wightman, DS | 1 |
| Modell, JG | 1 |
| Baldwin, DS | 1 |
| Pae, CU | 1 |
| Lim, HK | 1 |
| Han, C | 1 |
| Patkar, AA | 1 |
| Steffens, DC | 1 |
| Masand, PS | 1 |
| Lee, C | 1 |
| Hasegawa, H | 1 |
| Piacentini, MF | 1 |
| Sarre, S | 1 |
| Michotte, Y | 1 |
| Ishiwata, T | 1 |
| Meeusen, R | 1 |
| Kirksey, DF | 1 |
| Harto-Truax, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility Study of a Hypnosis Intervention and a Cognitive Behavioral Therapy Intervention to Reduce Fatigue in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer[NCT04999306] | 60 participants (Anticipated) | Interventional | 2023-05-17 | Recruiting | |||
| Effect of Resistance Training Variable Manipulation (Intensity and Volume) on Body Composition, Fatigability and Functional Capacity in Postmenopausal Breast Cancer Survivors.[NCT03644329] | 80 participants (Anticipated) | Interventional | 2018-05-13 | Recruiting | |||
| An 8 Week, Multicenter, Randomized, Double-blind, Placebo Controlled Comparison of the Efficacy of Extended Release Bupropion Hydrochloride and Placebo in the Treatment of Adult Outpatients With Major Depressive Disorder With Lethargic Symptoms[NCT00064467] | Phase 3 | 268 participants | Interventional | 2003-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for bupropion and Lassitude
| Article | Year |
|---|---|
Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review.
Topics: Adult; Bupropion; Fatigue; Humans; Neoplasms | 2023 |
Symptoms of fatigue and sleepiness in major depressive disorder.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Bupropion; Ce | 2006 |
Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Fatigue; Humans | 2007 |
9 trials available for bupropion and Lassitude
| Article | Year |
|---|---|
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial.
Topics: Adult; Aged; Bupropion; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration S | 2020 |
A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures.
Topics: Age Factors; Antidepressive Agents, Second-Generation; Breast Neoplasms; Bupropion; Cancer Survivors | 2020 |
Brief Behavioral Therapy and Bupropion for Sleep and Fatigue in Young Adults With Crohn's Disease: An Exploratory Open Trial Study.
Topics: Adolescent; Adult; Behavior Therapy; Bupropion; Crohn Disease; Fatigue; Female; Humans; Quality of L | 2022 |
Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Double-Blind | 2014 |
Fatigue-related impairments in oculomotor control are prevented by norepinephrine-dopamine reuptake inhibition.
Topics: Adult; Bupropion; Caffeine; Central Nervous System Stimulants; Dopamine Uptake Inhibitors; Fatigue; | 2017 |
The impact of bupropion on psychomotor performance.
Topics: Adult; Aerospace Medicine; Antidepressive Agents, Second-Generation; Bupropion; Cross-Over Studies; | 2002 |
An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cohort Studies; Delayed-Action Preparati | 2006 |
Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.
Topics: 4-Aminopyridine; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Depressi | 2006 |
9 other studies available for bupropion and Lassitude
| Article | Year |
|---|---|
Evaluating the effect of smoking cessation treatment on a complex dynamical system.
Topics: Bupropion; Craving; Drug Therapy, Combination; Fatigue; Humans; Nicotine; Smoking Cessation; Substan | 2017 |
Potential Role of Bupropion Sustained Release for Cancer-Related Fatigue: a Double-Blind, Placebo-Controlled Study
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action | 2018 |
Bupropion-related visual hallucinations in a veteran with posttraumatic stress disorder and multiple sclerosis.
Topics: Aged, 80 and over; Bupropion; Dopamine Uptake Inhibitors; Fatigue; Hallucinations; Humans; Male; Mul | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Fatigue; Female; Humans; Middle Aged; Multiple | 2010 |
Reward responsiveness and fatigue in multiple sclerosis.
Topics: Adult; Anxiety; Attention; Bupropion; Citalopram; Cognition; Depression; Disability Evaluation; Diso | 2013 |
Bupropion sustained release treatment reduces fatigue in cancer patients.
Topics: Adjustment Disorders; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiet | 2004 |
Influence of brain catecholamines on the development of fatigue in exercising rats in the heat.
Topics: Animals; Body Temperature Regulation; Brain; Bupropion; Catecholamines; Dopamine; Dopamine Uptake In | 2008 |
Private practice evaluation of the safety and efficacy of bupropion in depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents; Bupropion; Depressive Disorder; Dru | 1983 |